---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-048814"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:32:16.240949+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M

## Summary
- Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.
- Modified 2025 revenue guidance to $800-850M, citing capacity constraints at prior specialty pharmacy.
- Cash and investments $524.2M; repurchased $50.6M in stock during Q3.
- NDA for relacorilant in hypercortisolism PDUFA Dec 30, 2025; NDA for ovarian cancer PDUFA July 11, 2026.
- New oncology trials starting: Phase 2 in earlier-stage ovarian, endometrial, cervical, pancreatic cancers; Phase 1b for nenocorilant with immunotherapy.

## SEC filing metadata
- accession: 0001628280-25-048814
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/0001628280-25-048814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-048814
- JSON: https://secwatch.observer/filing/0001628280-25-048814.json
- Plain text: https://secwatch.observer/filing/0001628280-25-048814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.